Bladder Cancer Journal Vol. 10, Issue 1
Ensuring Successful Biomarker Studies in Bladder Preservation Clinical Trials for Non-muscle...
Read More
Topic: Advanced Disease
Bladder Cancer Journal Vol. 9, Issue 4
What is a Bladder Cancer Molecular Subtype? Abstract: BACKGROUND: Several molecular...
Read More
Bladder Cancer Journal Vol. 9, Issue 3
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is...
Read More
Bladder Cancer Journal Vol. 9, Issue 2
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer...
Read More
Point-Counterpoint: Erectile Dysfunction After Local Therapies: PDE5 Inhibitors and Early Penile Rehab Improves ED Recovery Following Radical Surgery – Pro
T. Mike Hsieh, MD, MBA, presents the pros of using PDE5 inhibitors and early penile rehabilitation to treat erectile dysfunction post-radical prostatectomy. In this presentation, Dr. Hsieh discusses, the role of tissue hypoxia in recovery failure, the changing ratios of collagen versus smooth muscle in the organ pre- and post-operation, and why Restoration of QoL, not Spontaneous Erection Recovery, should be the measure of success.
This lecture is part of a Point-Counterpoint debate. Its opposing lecture is “Point-Counterpoint: Erectile Dysfunction After Local Therapies: PDE5 Inhibitors and Early Penile Rehab Improves ED Recovery Following Radical Surgery–Con.”
Read More
Neoadjuvant Therapy for MIBC in the Genomic Era
Colin P.N. Dinney, MD, discusses the promise of neoadjuvant chemotherapy for muscle-invasive bladder cancer in the genomic era.
Read More
Prioritizing the Optimal Therapy for T1 Bladder Cancer: Using the Old and the New to Determine What to Do
Seth P. Lerner, MD, discusses the optimal therapy for T1 high-grade (T1HG) bladder cancer and considers the future of treatment.
Read More
Bladder Cancer Journal Vol. 9, Issue 1
Recent Advances in the Classification of Bladder Cancer – Updates from the 5th Edition of the...
Read More
Bladder Sparing Regimens for Muscle Invasive Disease: Should We Be Doing this More?
Peter Black, MD, FACS, FRCSC, discusses trimodal therapy (TMT) as a bladder-sparing option for some patients with muscle-invasive bladder cancer (MIBC).
Read More
The Contribution of SWOG to Bladder Cancer Clinical Trials
Seth P. Lerner, MD, provides a comprehensive history of Bacille Calmette-Guerin (BCG) and SWOG ’s innovation in bladder cancer over the past three decades.
Read More
Risk-Adapted TURBT
In this 20-minute video, Seth P. Lerner, MD, Professor of Urology and Vice-chair for Faculty Affairs in the Scott Department of Urology, and Director of Urologic Oncology and the Multidisciplinary Bladder Cancer Program at Baylor University, discusses risk-adapted transurethral resection of bladder tumor (TURBT). He assesses TURBT’s role in staging and treatment and considers its use in bladder preservation.
Read More
Bladder Sparing Tri-Modal Therapy Updates
In this 24-minute video, Daniel A. Hamstra, MD, PhD, Professor and Chair of Radiation Oncology at Baylor College of Medicine, discusses the viable but under-utilized therapy of trimodal bladder preservation. He specifically explores the role of surgery, chemotherapy, radiotherapy (RT), and check-point inhibitors in bladder sparing therapy.
Read More